Alaric W D'Souza1, Eshia Moodley-Govender2, Bertram Berla1,3, Tejas Kelkar1, Bin Wang1, Xiaoqing Sun1, Brodie Daniels2,4, Anna Coutsoudis2, Indi Trehan4,5, Gautam Dantas1,3,6,7. 1. Edison Family Center for Genome Sciences and Systems Biology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. 2. Department of Paediatrics and Child Health, University of KwaZulu-Natal, Durban, South Africa. 3. Department of Pathology and Immunology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. 4. HIV Preventin Research Unit, South African Medical Research Council, Durban, South Africa. 5. Department of Pediatrics, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. 6. Department of Molecular Microbiology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. 7. Department of Biomedical Engineering, Washington University in St Louis, St Louis, Missouri, USA.
Abstract
BACKGROUND: Prophylactic cotrimoxazole treatment is recommended in human immunodeficiency virus (HIV)-exposed, uninfected (HEU) infants, but the effects of this treatment on developing HEU infant gut microbiotas and resistomes are largely undefined. METHODS: We analyzed whole-metagenome sequencing data from 163 longitudinally collected stool samples from 63 HEU infants randomized to receive (n = 34; CTX-T) or to not receive (n = 29; CTX-N) prophylactic cotrimoxazole treatment. We generated taxonomic, functional pathway, and resistance gene profiles for each sample and compared microbiome signatures between the CTX-T and CTX-N infants. RESULTS: Metagenomic analysis did not reveal significant differences in taxonomic or functional pathway α-diversity between CTX-T and CTX-N infants. In contrast, resistance gene prevalence (P = .00719) and α-diversity (P = .0045) increased in CTX-T infants. These differences increased over time for both resistance gene prevalence measured by log-normalized abundance (4-month mean, 0.71 [95% confidence interval {CI}, .2-1.2] and 6-month mean, 0.85 [95% CI, .1-1.7]) and α-diversity (P = .0045). Unlike α-diversity, interindividual gut microbiome taxonomic (mean, -0.11 [95% CI, -.15 to -.077]), functional taxonomic (mean, -0.050 [95% CI, -.084 to -.017]), and resistance gene (mean, -0.13 [95% CI, -.17 to -.099]) β-diversity decreased in CTX-T infants compared with CTX-N infants. These results are consistent with persistent antibiotic selection pressure. CONCLUSIONS: Cotrimoxazole prophylaxis in HEU infants decreased gut microbiome β-diversity and increased antibiotic resistance gene α-diversity and prevalence. Antibiotic resistance is a growing threat, especially in low- and middle-income countries where the higher perinatal HIV exposure rates result in cotrimoxazole prophylaxis. Understanding effects from current HEU infant antibiotic prophylaxis guidelines will inform guideline revisions and efforts to reduce increasing antibiotic resistance.
BACKGROUND: Prophylactic cotrimoxazole treatment is recommended in human immunodeficiency virus (HIV)-exposed, uninfected (HEU) infants, but the effects of this treatment on developing HEU infant gut microbiotas and resistomes are largely undefined. METHODS: We analyzed whole-metagenome sequencing data from 163 longitudinally collected stool samples from 63 HEU infants randomized to receive (n = 34; CTX-T) or to not receive (n = 29; CTX-N) prophylactic cotrimoxazole treatment. We generated taxonomic, functional pathway, and resistance gene profiles for each sample and compared microbiome signatures between the CTX-T and CTX-Ninfants. RESULTS: Metagenomic analysis did not reveal significant differences in taxonomic or functional pathway α-diversity between CTX-T and CTX-Ninfants. In contrast, resistance gene prevalence (P = .00719) and α-diversity (P = .0045) increased in CTX-Tinfants. These differences increased over time for both resistance gene prevalence measured by log-normalized abundance (4-month mean, 0.71 [95% confidence interval {CI}, .2-1.2] and 6-month mean, 0.85 [95% CI, .1-1.7]) and α-diversity (P = .0045). Unlike α-diversity, interindividual gut microbiome taxonomic (mean, -0.11 [95% CI, -.15 to -.077]), functional taxonomic (mean, -0.050 [95% CI, -.084 to -.017]), and resistance gene (mean, -0.13 [95% CI, -.17 to -.099]) β-diversity decreased in CTX-Tinfants compared with CTX-Ninfants. These results are consistent with persistent antibiotic selection pressure. CONCLUSIONS:Cotrimoxazole prophylaxis in HEU infants decreased gut microbiome β-diversity and increased antibiotic resistance gene α-diversity and prevalence. Antibiotic resistance is a growing threat, especially in low- and middle-income countries where the higher perinatal HIV exposure rates result in cotrimoxazole prophylaxis. Understanding effects from current HEU infant antibiotic prophylaxis guidelines will inform guideline revisions and efforts to reduce increasing antibiotic resistance.
Authors: Duy Tin Truong; Eric A Franzosa; Timothy L Tickle; Matthias Scholz; George Weingart; Edoardo Pasolli; Adrian Tett; Curtis Huttenhower; Nicola Segata Journal: Nat Methods Date: 2015-10 Impact factor: 28.547
Authors: Molly K Gibson; Bin Wang; Sara Ahmadi; Carey-Ann D Burnham; Phillip I Tarr; Barbara B Warner; Gautam Dantas Journal: Nat Microbiol Date: 2016-03-07 Impact factor: 17.745
Authors: D M Thea; M E St Louis; U Atido; K Kanjinga; B Kembo; M Matondo; T Tshiamala; C Kamenga; F Davachi; C Brown Journal: N Engl J Med Date: 1993-12-02 Impact factor: 91.245
Authors: Fiona Fouhy; Caitriona M Guinane; Seamus Hussey; Rebecca Wall; C Anthony Ryan; Eugene M Dempsey; Brendan Murphy; R Paul Ross; Gerald F Fitzgerald; Catherine Stanton; Paul D Cotter Journal: Antimicrob Agents Chemother Date: 2012-09-04 Impact factor: 5.191
Authors: Kathleen M Powis; Sajini Souda; Shahin Lockman; Gbolahan Ajibola; Kara Bennett; Jean Leidner; Michael D Hughes; Sikhulile Moyo; Erik van Widenfelt; Haruna B Jibril; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Int AIDS Soc Date: 2017-11 Impact factor: 5.396
Authors: Winston E Anthony; Bin Wang; Kimberley V Sukhum; Alaric W D'Souza; Tiffany Hink; Candice Cass; Sondra Seiler; Kimberly A Reske; Christopher Coon; Erik R Dubberke; Carey-Ann D Burnham; Gautam Dantas; Jennie H Kwon Journal: Cell Rep Date: 2022-04-12 Impact factor: 9.995
Authors: Lívia Budziarek Eslabão; Gabriela Farias Gubert; Lucas Cafferati Beltrame; Isis M A Mello; Oscar Bruna-Romero; Carlos R Zárate-Bladés Journal: Cells Date: 2022-07-23 Impact factor: 7.666
Authors: Louise Afran; Kondwani C Jambo; Wilfred Nedi; David J C Miles; Anmol Kiran; Dominic H Banda; Ralph Kamg'ona; Dumizulu Tembo; Annette Pachnio; Eleni Nastouli; Brigit Ferne; Henry C Mwandumba; Paul Moss; David Goldblatt; Sarah Rowland-Jones; Adam Finn; Robert S Heyderman Journal: J Infect Dis Date: 2022-09-28 Impact factor: 7.759
Authors: Alaric W D'Souza; Manish Boolchandani; Sanket Patel; Gianluca Galazzo; Jarne M van Hattem; Maris S Arcilla; Damian C Melles; Menno D de Jong; Constance Schultsz; Gautam Dantas; John Penders Journal: Genome Med Date: 2021-06-07 Impact factor: 11.117